Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination

Journal of the Royal Society Interface

Volumn 14, Issue 136, 2017, Pages

  Masala, G L ^a,b   Lipsitch, M ^c   Bottomley, C ^a   Flasche, S ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Herd protection; Pneumococcus; Serotype competition; Vaccination

Indexed keywords

BIOPHYSICS; BIOTECHNOLOGY;

COMPETITIVE PRESSURE; HERD PROTECTION; PNEUMOCOCCAL VACCINATION; PNEUMOCOCCUS; SEROTYPES; TRANSMISSION INTENSITY; VACCINATION; VACCINE EFFICACIES;

VACCINES;

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; DRUG EFFICACY; HERD; HUMAN; NONVACCINE SEROTYPE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL VACCINATION; PREVALENCE; PROTECTION; SEROTYPE; VACCINATION; BIOLOGICAL MODEL; HERD IMMUNITY; IMMUNOLOGY; PATHOGENICITY; STREPTOCOCCUS PNEUMONIAE;

HUMANS; IMMUNITY, HERD; MODELS, IMMUNOLOGICAL; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 85040927916     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2017.0620     Document Type: Article

References (55)

1. Weinberger DM et al. 2009 Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 5, e1000476. (doi:10.1371/journal.ppat.1000476).
2. Henriques-Normark B, Tuomanen EI. 2013 The pneumococcus: Epidemiology, microbiology, and pathogenesis. Cold Spring Harb. Perspect. Med. 3, a010215. (doi:10.1101/cshperspect.a010215).
3. O'Brien KL et al. 2009 Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893-902. (doi:10.1016/S0140-6736(09)61204-6.
4. Centers for Disease Control and Prevention (CDC) 2016 Pink book-pneumococcal disease. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pneumo.pdf (accessed 15 June 2016).
5. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. 2015 Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: An observational cohort study. Lancet Infect. Dis. 3099, 1-9.
6. Moore MR et al. 2016 Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: A matched case-control study. Lancet Respir. Med. 4, 399-406. (doi:10.1016/S2213-2600(16)00052-7).
7. Angoulvant F et al. 2014 Early impact of 13-valent pneumococcal conjugate vaccine on communityacquired pneumonia in children. Clin. Infect. Dis. 58, 918-924. (doi:10.1093/cid/ciu006).
8. Harboe Z, Dalby T. 2014 Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Infect. Dis. 59, 1066-1073. (doi:10.1093/cid/ciu524).
9. Rückinger S, van der Linden M, Siedler A, von Kries R. 2011 Potential benefits from currently available three pneumococcal vaccines for children- population-based evaluation. Klin. Padiatr. 223, 61-64. (doi:10.1055/s-0030-1268465).
10. Weiss S, Falkenhorst G, van der Linden M, Imohl M, von Kries R. 2015 Impact of 10-And 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012. Euro Surveill. 20, 21057.
11. Olarte L et al. 2015 Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in U.S. children. Clin. Infect. Dis. 61, 767-775. (doi:10.1093/cid/civ368).
12. Greenberg D, Givon-Lavi N, Ben-Shimol S, Ziv JB, Dagan R. 2015 Impact of PCV7/PCV13 introduction on community-Acquired alveolar pneumonia in children, 5 years. Vaccine 33, 4623-4629. (doi:10.1016/j.vaccine.2015.06.062).
13. Bruce MG, Singleton R, Bulkow L, Rudolph K, Zulz T, Gounder P, Hurlburt D, Bruden D, Hennessy T. 2015 Impact of the 13-valent pneumococcal conjugate vaccine ( pcv13) on invasive pneumococcal disease and carriage in Alaska. Vaccine 33, 4813-4819. (doi:10.1016/j.vaccine.2015.07.080).
14. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. 2016 Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin. Infect. Dis. 63, 611-618 ciw347. (doi:10.1093/cid/ciw347).
15. Feikin DR et al. 2013 Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med. 10, e1001517. (doi:10.1371/journal.pmed.1001517).
16. Weinberger DM, Malley R, Lipsitch M. 2011 Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962-1973. (doi:10.1016/S0140-6736(10)62225-8).
17. Flasche S, Le Polain de Waroux O, O'Brien KL, Edmunds WJ. 2015 The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease. PLoS Comput. Biol. 11, e1004173. (doi:10.1371/journal.pcbi.1004173).
18. Weinberger DM, Malley R, Lipsitch M, Mulholland K, Satzke C. 2012 Serotype replacement after pneumococcal vaccination-Authors' reply. Lancet 379, 1388-1389. (doi:10.1016/S0140-6736(12)60591-1).
19. Alderson MR. 2016 Status of vaccine research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine 34, 2959-2961. doi:10.1016/j.vaccine.2016.03.107).
20. Flasche S, Edmunds WJ, Miller E, Goldblatt D, Robertson C, Choi YH. 2013 The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination. Proc. R. Soc. B 280, 20131939. (doi:10.1098/rspb.2013.1939).
21. Bottomley C, Roca A, Hill PC, Greenwood B, Isham V. 2013 A mathematical model of serotype replacement in pneumococcal carriage following vaccination. J. R. Soc. Interface 10, 20130786. (doi:10.1098/rsif.2013.0786).
22. Lipsitch M. 1997 Vaccination against colonizing bacteria with multiple serotypes. Proc. Natl Acad. Sci. USA 94, 6571-6576. (doi:10.1073/pnas.94.12.6571).
23. Trzciński K, Li Y, Weinberger DM, Thompson CM, Cordy D, Bessolo A, Malley R, Lipsitch M. 2015 Effect of serotype on pneumococcal competition in a mouse colonization model. MBio 6, e00902-e15. (doi:10.1128/mBio.00902-15).
24. Paterson GK, Mitchell TJ. 2006 Innate immunity and the pneumococcus. Microbiology 152, 285-293. (doi:10.1099/mic.0.28551-0).
25. Granat SM, Ollgren J, Herva E, Mia Z, Auranen K, Mäkelä PH. 2009 Epidemiological evidence for serotype-independent acquired immunity to pneumococcal carriage. J. Infect. Dis. 200, 99-106. (doi:10.1086/599364).
26. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. 2005 CD4 T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc. Natl Acad. Sci. USA 102, 4848-4853. (doi:10.1073/pnas.0501254102).
27. Lu Y-J et al. 2008 Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4, e1000159. (doi:10.1371/journal.ppat.1000159).
28. Cobey S, Lipsitch M. 2012 Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science 335, 1376-1380. (doi:10.1126/science.1215947).
29. Gray BM, Converse GM, Dillon HC. 1980 Epidemiologic studies of Streptococcus pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life. J. Infect. Dis. 142, 923-933. (doi:10.1093/infdis/142.6.923).
30. Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, George R, Miller E. 2011 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS ONE 6, e26190. (doi:10.1371/journal.pone.0026190).
31. Choi YH, Jit M, Flasche S, Gay N, Miller E. 2012 Mathematical modelling long-Term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PLoS ONE 7, e39927. (doi:10.1371/journal.pone.0039927).
32. Nurhonen M, Cheng AC, Auranen K. 2013 Pneumococcal transmission and disease in silico: A microsimulation model of the indirect effects of vaccination. PLoS ONE 8, e56079. (doi:10.1371/journal.pone.0056079).
33. Van Effelterre T et al. 2010 A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 28, 3650-3660. (doi:10.1016/j.vaccine.2010.03.030).
34. De Cao E, Melegaro A, Klok R, Postma M. 2014 Optimising assessments of the epidemiological impact in the Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling. PLoS ONE 9, e89415. (doi:10.1371/journal.pone.0089415).
35. Gjini E. 2017 Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7. Sci. Rep. 7, 3049. (doi:10.1038/s41598-017-02955-y).
36. Ojal J et al. 2017 Sustained reduction in vaccine-Type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data. Vaccine 35, 4561-4568. doi:10.1016/j.vaccine.2017.07.019).
37. Flasche S, Ojal J, Le Polain de Waroux O, Otiende M, O'Brien KL, Kiti M, Nokes DJ, Edmunds WJ, Scott JAG. 2017 Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: A modelling study based on data from PCV10 introduction in Kilifi, Kenya. BMC Med. 15, 113. (doi:10.1186/s12916-017-0882-9).
38. Melegaro A, Choi YYH, George R, Edmunds WJ, Miller E, Gay NJ. 2010 Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. Infect. Dis. 10, 90. (doi:10.1186/1471-2334-10-90).
39. Flasche S et al. 2016 The long-Term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-Attenuated dengue vaccine (Dengvaxia): A model comparison study. PLoS Med. 13, e1002181. (doi:10.1371/journal.pmed.1002181).
40. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, Kleinman K, Hinrichsen VL, Fraser C. 2010 Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2, 80-84. (doi:10.1016/j.epidem.2010.03.005).
41. Le Polain De Waroux O, Flasche S, Prieto-Merino D, Goldblatt D, Edmunds WJ. 2015 The efficacy and duration of protection of pneumococcal conjugate vaccines against nasopharyngeal carriage. Pediatr. Infect. Dis. J. 34, 858-864. (doi:10.1097/INF.0000000000000717).
42. Nurhonen M, Auranen K. 2014 Optimal serotype compositions for pneumococcal conjugate vaccination under serotype replacement. PLoS Comput. Biol. 10, e1003477. (doi:10.1371/journal.pcbi.1003477).
43. Tregnaghi MW et al. 2014 Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med. 11, e1001657. (doi:10.1371/journal.pmed.1001657).
44. Cutts FT et al. 2005 Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: Randomised, double-blind, placebo-controlled trial. Lancet 365, 1139-1146. doi:10.1016/S0140-6736(05)71876-6).
45. O'Brien KL et al. 2003 Efficacy and safety of sevenvalent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362, 355-361. (doi:10.1016/S0140-6736(03)14022-6.
46. Penny MA et al. 2016 Public health impact and cost-effectiveness of the RTS, S/AS01 malaria vaccine: A systematic comparison of predictions from four mathematical models. Lancet 387, 367-375. (doi:10.1016/S0140-6736(15)00725-4).
47. Rodgers GL, Klugman KP. 2011 The future of pneumococcal disease prevention. Vaccine 29(Suppl. 3), C43-C48. (doi:10.1016/j.vaccine.2011.07.047).
48. Malley R, Anderson PW. 2012 Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc. Natl Acad. Sci. USA 109, 3623-3627. (doi:10.1073/pnas.1121383109).
49. Fine P, Eames K, Heymann DL. 2011 'Herd immunity': A rough guide. Clin. Infect. Dis. 52, 911-916. (doi:10.1093/cid/cir007).
50. Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. 2005 Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J. Infect. Dis. 192, 367-376. (doi:10.1086/431679).
51. Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. 2007 Long-Term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae-And associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization-in HIVinfected and HIV-uninfected children. J. Infect. Dis. 196, 1662-1666. (doi:10.1086/522164).
52. Turner P, Hinds J, Turner C, Jankhot A, Gould K, Bentley SD, Nosten F, Goldblatt D. 2011 Improved detection of nasopharyngeal co-colonization by multiple pneumococcal serotypes using latex agglutination or molecular serotyping by microarray. J. Clin. Microbiol. 49, 1784-1789. (doi:10.1128/JCM.00157-11).
53. Satzke C, Dunne EM, Porter BD, Klugman KP, Mulholland EK. 2015 The PneuCarriage project: A multi-centre comparative study to identify the best serotyping methods for examining pneumococcal carriage in vaccine evaluation studies. PLoS Med. 12, e1001903. (doi:10.1371/journal.pmed.1001903).
54. Weinberger DM, Dagan R, Givon-Lavi N, Regev- Yochay G, Malley R, Lipsitch M. 2008 Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J. Infect. Dis. 197, 1511-1518. (doi:10.1086/587941).
55. Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. 2005 Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med. 2, e15. (doi:10.1371/journal.pmed.0020015).